Brief: Apontis Pharma Signs New In-Licensing Agreement For A New Single Pill
Sept 14 (Reuters) - APONTIS PHARMA AG APPHG.DE :
* ANNOUNCED SIGNING OF A NEW IN-LICENSING AGREEMENT FOR A
NEW
SINGLE PILL
* MARKET LAUNCH IN GERMANY IS PLANNED FOR EARLY 2022
Source text for Eikon: ID:nEQ9tsRTGa
Further company coverage: APPHG.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Apontis Pharma AG
See all newsBrief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
Brief: APONTIS PHARMA Q1 EBITDA EUR 1.3 Million
Brief: Apontis Pharma Says Zentiva AG Submits Formal Request To Carry Out A Merger
Brief: Zentiva Says Amendeds Offer To Acquire Each Outstanding Share Of Apontis Pharma In Cash By Waiving Condition Of A Minimum Acceptance
Brief: Apontis Pharma: Zentiva To Launch Voluntary Public Purchase Offer At EUR 10.00 Per Share